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Design and optimization of a probiotic tablet for gastrointestinal tolerance by a
simplex-centroid mixture
Mohd Akmal Azhar and Mimi Sakinah Abdul Munaim
Faculty of Chemical and Process Engineering Technology, Universiti Malaysia Pahang, Lebuhraya Tun Razak, Kuantan, Malaysia
ABSTRACT
In this study, a simplex-centroid mixture design using design of experiment (DOE) software was imple-
mented to evaluate the effect of biopolymers as excipients, which are hydroxypropyl methylcellulose, and
alginate, on the gastrointestinal tolerance of probiotic tablet containing Saccharomyces boulardii. Microbial
viability and dissolution time were used to evaluate the ideal formulation made using 39.01% carboxyme-
thylcellulose and 60.99% alginate as excipients, which protected the probiotics from the acidic condition
in the stomach with good dissolution time. The formulated probiotic tablet is more stable in terms of via-
bility when stored at 4 C compared to room temperature. However, the viability remains above 106 CFU/
tablet after six months of storage at room temperature. This study shows that the simplex-centroid mix-
ture design is valid and can be used to formulate probiotic tablets that possess gastrointestinal tolerance.
This study can lead to the development of commercial production of probiotic yeast tablets with gastro-
intestinal tolerance.
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Probiotics are microorganisms such as bacteria and yeast that are
orally introduced into the human digestive system and favorably
respond to the digestive system to confer health benefits to the
host. In the last decade, various studies regarding probiotic cells
have determined them to benefit the human body. Probiotics
function by maintaining a good intestinal microbial community,
preventing the development of pathogenic microbes, activating
the defending host system, relieving constipation, synthesizing
vitamins and antimicrobials, and enhancing calcium absorption
when there are sufficient probiotics in the colon [1,2].
One of the main issues for the oral probiotic formulation is
probiotic microorganisms’ viability because they are expected to
be administered and transported viably to the target side. Some
researchers suggested that the probiotics’ viability must be main-
tained at 106 CFU/g or more to make it beneficial [3]. Others said
that it must be maintained at 108 CFU/g [4] and 109 CFU/g to
1012 CFU/g [5]. This remains a significant problem for manufac-
turers and customers, as the probiotics can only be beneficial to
the host if adequate viable cells are delivered to the target site
after surviving the acidic condition in the gastrointestinal tract.
Generally, various probiotic strains are sensitive to acidic condi-
tions. They could not survive the stomach’s gastric juice unless
they possess acidic tolerance or have some form of protection
such as coating or encapsulation [6]. Therefore, it is necessary to
develop formulations that protect the probiotics from gastric pH
and harsh conditions in the human stomach.
The probiotic formulation in a tablet matrix form or the mono-
lithic matrix system is one of the ideal techniques to protect the
probiotics from the harsh condition in the gastrointestinal tract,
for instance, the extreme condition of the bile salt and acidic pH
[7]. The matrix tablet formulation can be developed to improve
the colonization of probiotic cells on the inner layer of the gastro-
intestinal tract. Additionally, the tablet dosage form offers some
advantages compared to other dosage forms, such as enhancing
microorganism stability at extreme temperatures, low cost for
large-scale production, precise dosing, and ease of handling [8].
Moreover, with a suitable excipient formulation, a probiotic tablet
can be formulated to regulate the release and delivery of pro-
biotic cells to the target location in the gastrointestinal system [9].
In the tablet production process, biopolymers can be used as
an excipient in the formulation. Alginate is one of the most com-
mon compounds integrated as an excipient for probiotic encapsu-
lation because of its nontoxicity and biocompatibility. Moreover,
this biopolymer is popular because of its low cost. It forms a gel
when interacting with an aqueous medium and acts as a diffusion
barrier for the probiotic cells as an active component in the for-
mulation [10]. Hydroxypropyl methylcellulose (HPMC) is another
essential biopolymer in the development of probiotic tablets. It
forms a hydrogel layer by hydrating and swelling once it comes
in contact with a liquid medium [11]. Therefore, it can regulate
the diffusion of liquid into the tablet core, thus controlling
the dissolution of the active ingredient inside the tablet.
Carboxymethylcellulose (CMC) is another excellent biopolymer
that improves the diffusion or dissolution system of tablet matrix
design [12]. Generally, it facilitates the release of the active ingre-
dient by hydrating the matrices, then diffusing the active ingredi-
ent into the bulk solution. It can achieve a constant delivery rate
of active ingredient by partial dissolution or erosion. The chemical
structures of alginate, HPMC, and CMC are shown in Figure 1.
One of the approaches to design and formulate pharmaceutical
tablet dosage form is by using design of experiment (DOE) soft-
ware. It is a type of statistical experimental design used in many
fields, including pharmaceutical, engineering, and food industries.
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This is a systematic approach to understand how the process and
product parameters influence response variables such as process-
ability, physical properties, or product output [13].
One of the DOE designs named the simplex-centroid mixture
approach can be used to obtain the optimum formulation with
the minimum number of experiments. It can be customized to
select a suitable condition to obtain an optimized response
through various specific components in the formulation [14].
Moreover, one of the advantages of using a mixture experiment
design is the reduction of experiments required to assess multiple
variables. This approach can also classify the interaction statistic-
ally, which can overcome the shortcoming of the traditional meth-
ods of the formulation [15].
Most of the previous studies for acidic tolerance are related to
lactic acid probiotics. Few reports exist regarding probiotics from
yeast compared to bacterial strains, although it has a good poten-
tial of probiotic ability that can benefit human health. Compared
to bacterial probiotics, products containing yeast are not as widely
available but are fast developing and becoming more common. In
our previous study, a potential probiotic yeast was identified and
evaluated for use in new probiotic yeast formulations or food sup-
plements [16,17]. Therefore, the purpose of the current study is to
achieve the ideal formulation for the probiotic tablets containing
Saccharomyces boulardii with optimum dissolution time and high
viable counts when coming in contact with low pH in the human
stomach. Many studies regarding acidic tolerance used individual
polymers or materials to encapsulate the probiotic strains. In this
study, the optimal mixture design using Design-Expert software
was implemented to optimize a combination of excipients from
different functional polymers, which are CMC, HPMC, and alginate.
In this study, the tablet matrix dosage form was formulated using
the direct compression method, which has few manufacturing
steps and is an economical process compared to other methods
in the industry. This form can be used as a product in the
Figure 1. Chemical structures of (a) alginate, (b) HPMC, and (c) CMC.
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pharmaceutical field to ensure that the active cells are protected
from the harsh condition and delivered into the intestinal tract.
Materials and methods
Preparation of probiotic powder
Saccharomyces boulardii that was isolated and screened as a pro-
biotic strain from the previous study [17] was cultured and formed
into powder by freeze-drying. The yeast was grown at 37 C for
24 h in a YEPD medium. The cells were then harvested by a high-
speed centrifuge (5810 R, Eppendorf) at 4000 rpm for 15min [18].
An equal volume of 10% skim milk was added to the cells as a
cryoprotectant. Then, a vacuum freeze dryer (BTP-8ZL00X, SP
Scientific) was used to freeze-dry the mixture.
Preparation of tablets containing probiotic cells
A direct compression method was used to prepare the probiotic
tablets. The process was started by mixing the freeze-dried pro-
biotic powder containing Saccharomyces boulardii with other mate-
rials in the mixer VMD-AC (Shakti). The mixture was then
compressed into tablet form using a rotary tablet machine (UET-6D,
UEC Unity Equipment Co.), using a 12mm oblong mold and com-
pression force required to produce tablets with a hardness of about
25N. The targeted tablet weight of 0.2 g was set to produce about
1000 tablets containing freeze-dried probiotic yeast, talc, magne-
sium stearate, CMC (Sigma), HPMC K4M pharmaceutical grade
(Emory), and sodium alginate (R&M chemical) with different frac-
tions based on the mixture design suggested by the DOE software.
Experimental design
The level of independent variables was based on the preliminary
study (data not shown). Probiotic matrix tablets were formulated
according to the design generated using Design Expert software
version 11. A 13-run, three-factor, simplex centroid mixture design
having three center points and three replicate runs were used to
study the effect of formulation (independent) on microbial viabil-
ity percentage and dissolution time (dependent variable).
Polynomial models were generated for the responses Y1 (% micro-
bial viability) and Y2 (dissolution time). The linear model was
chosen based on the p-value for F value and lack of fit. The com-
position of the formulation was predicted by the model, which
would provide the desired viability and dissolution time profile.
Simulated gastric fluid (SGF) preparation
The SGF was prepared according to a modified USP 35 method
[19]. Two grams of sodium chloride and 3.2 g of purified pepsin
were dissolved in sterile purified water. Next, 1mL of concentrated
hydrochloric acid was added to adjust the pH, and sterile water
was added to make 1 L. The pH of the test solution was approxi-
mately 2.
Simulated intestinal fluid (SIF) preparation
The SIF was prepared according to USP 35 method [19]. First,
6.8 g of monobasic potassium phosphate was dissolved in 250mL
of purified water. Next, 77mL of sodium hydroxide (0.2 N), 10 g of
pancreatin, and 500mL of purified water was added to the solu-
tion. The solution pH was adjusted to 6.8 ± 0.1 by using 0.2 N of
sodium hydroxide or 0.2 N of hydrochloric acid. Lastly, purified
water was added to make 1 L.
Treatment of probiotics in SGF
This procedure was modified from Jamilah et al. [20]. Samples
were incubated for 3 h in 100mL of SGF at 37 C to mimic the
human stomach condition with stirring at 200 rpm using an incu-
bator shaker to mimic bowel movement. The undissolved samples
were transferred to 100mL of SIF after 3 h. If the samples dis-
solved in the SGF, 1mL of SGF was collected and transferred to
SIF. One milliliter of each suspension was removed and evaluated
for the survivability of the probiotic cells.
Treatment of probiotics in SIF
This procedure was modified from Jamilah et al. [20]. After the
gastric treatment using SGF, the undissolved samples or 1mL of
SGF samples were transferred into 100mL of SIF and incubated at
37 C and 200 rpm for 2 h. Then, 1mL of each suspension was
removed and evaluated for the survivability of the probiotic cells.
Assessment of cell survival
The evaluation of probiotics survival was based on Chiron et al.
[21]. For each sample, 500 mL of cell suspension was collected.
Next, 5 mL of thiazole orange (TO) solution and propidium iodide
(PI) dye solution (BD cell viability kit) was added to the samples.
The samples were then vortexed and incubated for at least 5min
at room temperature. The samples were passed through a flow
cytometer (Accuri C6), and the data were collected using the FL1
versus FL3 dot plot. All experiments were conducted in triplicate.
The percentage of microbial viability was calculated by using the
formula [22]:
Viability %ð Þ ¼ B
A  100 (1)
where A and B are viable counts before and after the gastric treat-
ment, respectively.
Storage stability experiment
The tablets were stored at two different temperatures to validate
the stability storage for the optimized tablet formulation. The tab-
lets were sealed using plastic packaging and stored at 25 and 4 C
to verify the stability of the probiotic yeast tablets and examine
the effect of different storage temperatures on them. The viability
of the probiotic yeast inside the tablet was measured every
two weeks.
Statistical evaluation
The data analysis including mixture and model, were conducted
using Design Expert software version 11.
Results and discussions
Preparation of probiotic tablet
The tablet compression process resulted in tablet hardness around
25N, with a total of 13 different formulations suggested by the
software. The three functional polymers only comprise 67% excipi-
ent. Other static components in the tablet formulation are 30%
probiotic yeast powder as the active ingredient, 2% talc as glidant,
and 1% magnesium stearate as lubricant.
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Mixture optimal design results and analysis of variance
The mixture design of the simplex-centroid approach was used
with the help of Design-Experts to optimize the tablet formulation
with three different functional polymers for gastrointestinal toler-
ance (X1: CMC, X2: HPMC, X3: Alginate). The design and the
experimental results containing three replicates and ten model
points are shown in Table 1. The evaluated response variables are
Y1: microbial viability and Y2: dissolution time.
In this experiment, formulations 11, 12, and 13 are considered
as replication models. A replication model is important to deter-
mine the precision of estimates effect and gives additional infor-
mation on background process variation. A replication model can
also be used to estimate pure error. It can provide information
about the adequacy and efficiency of the specified model, known
as a lack-of-fit test. The lack-of-fit tests and the comparison of the
sequential model are summarized in Table 2. Statistically, the
model properly explains the response based on the significant p-
value (<.0001) of the response Y1 for the linear and quad-
ratic models.
On the other hand, the special cubic and cubic models did not
fit the data because of the large p-value (>.05). Similarly, the lin-
ear and quadratic models for Y2 indicate that it fits the data with
a low p-value (<.05) of .0016 and .0014, respectively. As seen in
Table 2, the large p-values (.2246 and .1649 for Y1 and Y2,
respectively) of the lack-of-fit test indicate that the quadratic
model can be accepted. A lack-of-fit test diagnoses whether a
model sufficiently fits the data. It is based on the residual sum of
squares calculation [23]. Hence, the regression model of both val-
ues of the response is valid and applicable for the analysis of
microbial viability (Y1) and dissolution time (Y2).
The adjusted coefficients of determination (adjusted R2) of the
equations Y1 and Y2 for the quadratic model are 0.9954 and
0.9417, respectively, indicating that 99.54% and 94.17% of the
results can be explained by the equations. The small difference
(<0.2) between the adjusted coefficients of determination
(adjusted R2 ¼ 0.9954) and predicted coefficients of determination
(predicted R2 ¼ 0.9920) for Y1 indicates that Equation (2) is well
fitted. Similarly, the other equations are also well fitted. A quad-
ratic multinomial regression fitting was performed; the regression
model was set by two indicators, and the following multiple
regression equations were obtained:
Y1 ¼ 16:89Aþ 66:32Bþ 93:83C þ 20:92ABþ 132:57AC þ 20:46BC
(2)
Y2 ¼ 2:01Aþ 12:42Bþ 6:18C  20:12AB 13:55AC þ 24:93BC
(3)
Analysis of variance (ANOVA) in Table 3 shows that the linear
mixture components for AC (pAC < .0001) are significant model
terms, indicating that the interaction between CMC and alginate
has the greatest impact on Y1 (microbial viability) of probiotics
tablets. In addition, the interaction between AB and BC also has a
notable impact on the viable counts of probiotics, as their p-val-
ues are less than .05 (pAB ¼ .0236 and pBC ¼ .0258). Moreover, the
linear components, AB, BC, and AC show a significant impact on
the response value Y2 (dissolution time) because the p-value is
lower than .05. Additionally, components AB and BC show the
greatest impact on the response because of their lowest p-values.
Effect of mixture component and formulation optimization
The contour map and the three-dimensional response surface of
each element can visually demonstrate the relationship between
the components of the mixing design of probiotic tablet
formulation.
As shown in Figure 2(a), a high value of Y1 is observed at ver-
tex C, where a higher percentage of C (alginate) is required for
the maximum microbial viability percentage of probiotic tablets
after acidic treatment. On the other hand, Figure 2(b) shows that
a higher percentage of component A (CMC) and a low percentage
of component B (HPMC) and component C (alginate) are required
for the minimum dissolution time.
The coefficients (Table 4) of the equation to microbial viability
(Y1) suggest that the linear terms present a high contribution of
alginate (C), followed by HPMC (B) and CMC (A). There is an
increase in viability when alginate or a binary mixture of CMC and
alginate was used. In addition, for dissolution time (Y2), the linear
term indicates that CMC provides the highest results for the min-
imum dissolution time, followed by alginate and HPMC. However,
for the binary mixture, a combination of CMC and HPMC (AB)
gives the highest value, followed by the combination of CMC and
alginate (AC). On the other hand, the combination of HPMC and
alginate (BC) has a negative effect on the response Y2.
The total time for food to move through the human stomach
ranges around 2.5–4 h. Meanwhile, the pH in the gastric juice
range around 2–3 after food consumption and can decrease to 1
during fasting [24]. Therefore, pH 2 was chosen as a significant
value for this analysis of simulated gastric resistance, and 3 h was
selected as the processing time. Probiotic microorganisms should
be viable and reach their target of action alive. Thus, the probiotic
product needs to have some protection from the gastric juice. The
viability of the probiotics after acidic treatment varies depending
on the ability of the matrix tablet to retain its form without being
dissolved in the acidic medium. Based on the contour map and
surface plot in Figure 2(a), alginate is an important component to
protect the probiotics from gastric pH because of its ability to
form a gel in acid if the pH is below its pKa (3.3–3.5) [25]. This
ability is conferred by the presence of the carboxylic acid group
in the alginate structure. This is one of the useful properties of
alginate for enteric delivery vehicles.
Table 1. The simplex-centroid mixture design and results of the experiment.
Formulation X1 X2 X3 Y1 (%) Y2 (H)
1 1.00 0.00 0.00 17.95 2.00
2 0.00 1.00 0.00 65.46 12.00
3 0.00 0.00 1.00 93.88 5.50
4 0.50 0.50 0.00 46.92 3.00
5 0.50 0.00 0.50 89.06 1.50
6 0.00 0.50 0.50 86.32 17.00
7 0.33 0.33 0.33 80.43 5.20
8 0.67 0.17 0.17 55.67 2.00
9 0.17 0.67 0.17 69.33 8.40
10 0.17 0.17 0.67 90.97 5.90
11 1.00 0.00 0.00 15.52 1.50
12 0.00 1.00 0.00 67.45 13.00
13 0.00 0.00 1.00 94.52 7.00
Table 2. Model comparison for the sequential and lack of fit for the
design model.
Type of model
Sequential Lack of fit
Adjusted R2 Predicted R2p-value p-value
Y1 Y2 Y1 Y2 Y1 Y2 Y1 Y2
Linear <0.0001 0.0016 0.0014 0.0167 0.8239 0.6676 0.7520 0.5879
Quadratic <0.0001 0.0014 0.2246 0.1649 0.9954 0.9417 0.9920 0.7858
Special cubic 0.9128 0.0728 0.1642 0.2690 0.9947 0.9619 0.9705 0.7848
Cubic 0.5670 0.2050 0.0746 0.3335 0.9940 0.9741 0.7539 0.5242
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Alginate is a linear polysaccharide consisting of 1!4 linked
b-(D)-glucuronic (G) and a-(L)-mannuronic (M) acids. It is commer-
cially available and well suited for the encapsulation of microor-
ganisms since it has generally recognized as safe (GRAS) status, is
nontoxic, and has a mild gelling form [26]. It is a suitable com-
pound that acts as a diffusion barrier for an active component,
such as probiotics. Alginate particles are easily broken down in
the intestines, but stable in gastric juice because the gels are sta-
bilized by the intermolecular hydrogen bonding network if the pH
is below the pKa of uronic acid [27].
In the pharmaceutical industry, alginate has been used in
many applications in controlled release oral dosage form as a car-
rier in the hydrophilic matrix because of its ability to form viscous
solution and gel when coming in contact with aqueous media.
The potential application of alginate on the drug release proper-
ties in the matrix tablet has been widely described in the litera-
ture [28,29]. Huq et al. [10] also reported that alginate exhibits
similar characteristics to tablets. The combination of alginate with
HPMC and CMC (Figure 2) could form more viscous gels at gastric
pH, representing an excellent matrix for protection of the probiot-
ics. The combination of alginate and CMC is also a promising
matrix for probiotics application as a dietary supplement [30].
CMC could be another important biopolymer for probiotic tab-
let development. CMC or cellulose gum is a cellulose derivative
with carboxymethyl groups (–CH2–COOH) bound to some of the
Table 3. Analysis of variance (ANOVA) for the quadratic model of response Y1 and Y2.
Source
Y1 Y2
Sum of squares df Mean square F value p-value Sum of squares df Mean square F value p-value
Model 8666.62 5 1733.32 520.84 <.0001 282.44 5 56.49 39.74 <.0001
Linear mixture 7414.78 2 3707.39 1114.02 <.0001 211.39 2 105.7 74.35 <.0001
AB 27.65 1 27.65 8.31 .0236 25.59 1 25.59 18 .0038
AC 1110.71 1 1110.71 333.75 <.0001 11.6 1 11.6 8.16 .0244
BC 26.44 1 26.44 7.95 .0258 39.29 1 39.29 27.64 .0012
Residual 23.3 7 3.33 9.95 7 1.42
Lack of fit 18.16 4 4.54 2.65 .2246 8.2 4 2.05 3.51 .1649
Pure rrror 5.14 3 1.71 1.75 3 0.5833
Correlation total 8689.91 12 292.39 12
Figure 2. Surface and contour plot of mixture analysis for (a) viability and (b) dissolution time.




A: CMC 16.89 2.01
B: HPMC 66.32 12.42
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hydroxyl groups of the glucopyranose monomers that make up
the cellulose backbone. As seen in Figure 2(b), the minimum dis-
solution time is affected by the higher percentage of CMC. This is
due to the super disintegrant property of CMC when coming into
contact with an aqueous medium, where it will swell immediately
and become larger than its original volume. The minimum dissol-
ution time is achieved when water reaches deep into the core of
the tablet, resulting in the maximum water uptake in a short
period [31]. This result is consistent with the literature [12,32,33]
where many pharmaceutical preparations in the tablet dosage
form use CMC in a sustained-release application. The role of CMC
is important in synthesizing the probiotic tablet because, without
the proper amount of disintegrant, it will be inappropriately dis-
solved or diffused. This may affect the delivery of the probiotics
to the target side, thus reducing the effectiveness. Additionally,
according to the FDA Select Committee on GRAS Substances,
CMC is virtually unabsorbed and generally regarded as safe when
used in reasonable quantities [34].
The study is based on the percentage of tablet dissolution
time and microbial viability. The optimization function of the soft-
ware was used to set the variation range of each component to
acquire good probiotic tablets containing a minimum dissolution
time and a high percentage of microbial viability. Then the
expected response value was set. Response values for the viability
were configured as maximum, while the dissolution time as min-
imum. All factors and responses with their restrictions are shown
in Table 5.
After the software runs, the experimental prediction was car-
ried out from the random combination until the target response
value was obtained. At the same time, four groups of formulations
close to the target response value were optimized by the Design-
Expert software, as shown in Table 6. The first group was used for
the verification of the optimal formula of probiotic tablets.
An interesting result was obtained when examining the predic-
tion results after the optimization. Based on the software analysis,
the HPMC alone or in combination with CMC has a significant
impact on protecting the probiotic tablet because of the ability to
form hydrogel surrounding the tablet. However, the best combin-
ation predicted by the software to obtain higher microbial viability
and lower dissolution time only required 39.01% CMC and 60.99%
alginate without HPMC for the excipient ratio. This may be
because alginate and HPMC have a common characteristic of per-
forming a diffusion barrier when coming in contact with an aque-
ous medium. On the other hand, when comparing the strength of
these two components in terms of hydrogel layer forming, the
alginate is a more significant and better excipient compared to
HPMC. However, not all probiotic formulation tablet designs for
gastrointestinal tolerance will have the same effect. Different com-
binations of polymers or materials might be good to produce
higher viability depending on many factors. Elements such as the
tablet encapsulation method, materials used, environmental condi-
tions, and probiotic strain play an important role in the gastro-
intestinal tolerance formulation. For example, the Lactobacillus
strains used in the study by Klayraung [35] showed higher viability
in a low pH medium when a polymer combination of HPMC and
alginate was used, while Graff [36] showed that individual polymer
like HPMC produced better acidic tolerance for
Saccharomyces strains.
Validation of the model
Based on the desirability criteria (maximum desirability ¼ 1), the
formulation with the highest desirability was chosen for confirm-
ation and final optimization of the probiotic tablet. The optimal for-
mula obtained by software optimization comprised 39.01% CMC,
0% HPMC, and 60.99% alginate. This consisted of 67% excipient in
the formulation. Other static ingredients included 30.0% probiotic
cell powder, 1.0% magnesium stearate, and 1.0% talc. The pre-
dicted response values under this formulation were expected to
obtain microbial viability of 95.36% and dissolution time of 1.3 h.
Three confirmatory experiments were carried out, and a microbial
viability of 94.13 ± 2.0% and dissolution time of 1.6 ± 0.3 h for the
tablets were obtained. A t-test was performed to confirm the con-
cordance between the experimental and predicted values. There
was no significant difference from the predicted values (p> .05),
indicating that the optimal formulation of probiotic tablets can be
accurately predicted using the simplex-centroid mixture design.
Storage stability
Cell viability over a storage period is an essential criterion to sig-
nify the effectiveness of the formulation in a stability test for long
shelf life. The viability of the probiotic cells in different storage
temperatures is shown in Figure 3. The tablets were stored at 4
and 25 C to compare the effect of storage temperature toward
the viability of probiotic yeast cells.
Initially, for both temperatures, the viable count of yeast probi-
otics was log 7.49 CFU/tablet. Afterwards, the number of viable
cells obtained after 24weeks of storage at 4 C storage decreased
to log 7.31 CFU/tablet, or about 0.18-log reduction. On the other
hand, the storage temperature of 25 C reduced the viable cell
count to log 7.27 CFU/tablet by approximately 0.22-log reduction
after two weeks of storage. Moreover, the viable cell decreased
significantly by about 0.57-log over 24weeks of storage time. This
is because Saccharomyces boulardii is a mesophile, and its growth
and metabolism occur naturally at room temperature. Therefore,
the viability dropped when the tablets were stored at room tem-
perature compared to cold storage, where the metabolic rate is
slowed down, thus maintaining the viability and extending the
shelf life [37]. These results are in line with a recent study [38]
showing that probiotic tablet bacteria showed a significant
decrease in viability when stored at room temperature compared
to at 4 C. These results show that storage temperature has a sig-
nificant impact on microbial viability, and a high level of mortality
is recorded when the temperature increased from 4 C to room
temperature, which is 25 C. These findings suggest that the for-
mulated tablets are stable when refrigerated, which is a common
practice for probiotic products.
Although the probiotics viability when stored at 25 C was
lower than that of 4 C after 24weeks (8.3 106 CFU/tablet), it still
achieved the minimum cell viability for the probiotics to confer
the desired health benefits stated by FAO/WHO, which is at least
106 CFU/g or mL sample. This result indicates that lyophilization
of this probiotic yeast using a freeze-drying process increases cell
survival and protects the cells during storage periods. Several the-
ories have been made regarding the maintaining of cell viability
during storage by the addition of cryoprotectant in the freeze-dry-
ing process, including damage protection of the cell wall or cell
Table 5. The target range of the test factors and response values.
Factor/Response Goal Lower limit Upper limit
A: CMC In range 0 100
B: HPMC In range 0 100
C: Alginate In range 0 100
Y1: Microbial viability Maximum 15.52 94.52
Y2: Dissolution time Minimum 1.5 17
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membrane and reduction of cell death rate [39]. Moreover, differ-
ent strains of the same species differ in their ability to maintain
viability during the storage period. Freeze-drying is a well-known
method of dehydration commonly used for microorganism preser-
vation. It is also widely used in food preservation and for several
medicinal uses, including protein-based medicines.
Conclusion
In this research, a monolithic tablet matrix formulation for pro-
biotic yeast cell having gastrointestinal tolerance was obtained
using a useful method which is simplex-centroid mixture based
on statistical analysis. A ternary blend of CMC, HPMC, and alginate
was evaluated by the centroid mixture design model. HPMC and
alginate increased the viability in acidic conditions because of the
viscous or gelling ability in the acidic medium, while CMC
improved the diffusion or dissolution of the tablet, thus helping
effective delivery of probiotic cells to the target site. According to
the polynomial model simulated by the software, the optimized
formulation is expected to have 95.36% viability after passing
through the acidic gastrointestinal environment and take 1.33 h
for dissolution using an excipient combination containing 39.01%
CMC and 60.99% alginate.
In addition, the analysis indicates that the formulated probiotic
yeast tablet is more stable when refrigerated in terms of viable
cell count compared to being stored at room temperature for a
six-month storage period. However, the viability after storage at
room temperature was still maintained at the minimum value for
commercial probiotic products as suggested by FAO/WHO, which
is more than 106 CFU/g or mL of sample. Therefore, this study
shows that the design using the mixture concept is reliable to for-
mulate probiotic yeast tablets containing CMC, HPMC, and algin-
ate that exhibit high viability even under acidic conditions and
offer ideal stability for commercial purposes.
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